Ozempic (Semaglutide) and Wegovy (Egmpegricitabine/Viltolarsen) are two drugs that are FDA approved for the treatment of obesity and weight loss.
Ozempic is a glucagon-like peptide 1 (GLP-1) receptor agonist that helps regulate blood sugar levels and reduce appetite. It is given as a once-weekly injection and can lead to significant weight loss in combination with diet and exercise. It works by slowing down digestion and reducing the amount of food you eat, as well as increasing feelings of fullness and reducing hunger.
Wegovy, on the other hand, is a RNA-targeted antisense oligonucleotide that works by reducing the production of a protein called proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 plays a role in regulating cholesterol levels, and by reducing its production, Wegovy can lower low-density lipoprotein (LDL) cholesterol, also known as “bad” cholesterol.
In clinical trials, patients treated with Wegovy lost weight, and those with elevated cholesterol levels had significant reductions in their levels. Unlike Ozempic, Wegovy is given as a monthly subcutaneous injection.
Both drugs have been found to be effective for weight loss, but it is important to note that weight loss results may vary from person to person, and that a healthy diet and exercise regimen should still be followed while taking these medications. Additionally, both drugs have potential side effects, including nausea, vomiting, and diarrhea for Ozempic, and muscle pain and fatigue for Wegovy.